Literature DB >> 9221302

[Drug therapy of ventricular arrhythmias].

S H Hohnloser1.   

Abstract

In patients with no or only mild structural heart disease, spontaneous ventricular ectopy which causes symptoms is being treated with beta receptor antagonists, sotalol, or in rare cases with class I substances. For primary prevention of sudden death, for instance in survivors of myocardial infarction, beta receptor antagonists are the only substances for which benefit has been demonstrated in large scale trials. In contrast, class I agents are contraindicated for this purpose. In secondary prevention of sudden death in patients with a history of sustained ventricular tachycardia or ventricular fibrillation, treatment with sotalol or amiodarone can be considered. However, nonpharmacological therapy by means of implantable defibrillators is increasingly applied in this patient population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9221302     DOI: 10.1007/bf03043259

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  11 in total

1.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

Authors:  A L Waldo; A J Camm; H deRuyter; P L Friedman; D J MacNeil; J F Pauls; B Pitt; C M Pratt; P J Schwartz; E P Veltri
Journal:  Lancet       Date:  1996-07-06       Impact factor: 79.321

2.  Beta blockade during and after myocardial infarction: an overview of the randomized trials.

Authors:  S Yusuf; R Peto; J Lewis; R Collins; P Sleight
Journal:  Prog Cardiovasc Dis       Date:  1985 Mar-Apr       Impact factor: 8.194

3.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Authors:  A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

4.  Antiarrhythmics Versus Implantable Defibrillators (AVID)--rationale, design, and methods.

Authors:  A P Hallstrom; H L Greene; D G Wyse; D Zipes; A E Epstein; M J Domanski; E B Schron
Journal:  Am J Cardiol       Date:  1995-03-01       Impact factor: 2.778

5.  Canadian Implantable Defibrillator Study (CIDS): study design and organization. CIDS Co-Investigators.

Authors:  S J Connolly; M Gent; R S Roberts; P Dorian; M S Green; G J Klein; L B Mitchell; R S Sheldon; D Roy
Journal:  Am J Cardiol       Date:  1993-11-26       Impact factor: 2.778

6.  Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators.

Authors:  J Siebels; R Cappato; R Rüppel; M A Schneider; K H Kuck
Journal:  Am J Cardiol       Date:  1993-11-26       Impact factor: 2.778

7.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

8.  Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators.

Authors: 
Journal:  Am J Cardiol       Date:  1993-08-01       Impact factor: 2.778

9.  Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction.

Authors:  W J Rogers; L J Bowlby; N C Chandra; W J French; J M Gore; C T Lambrew; R M Rubison; A J Tiefenbrunn; W D Weaver
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

10.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.